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Abstract
New diagnostics and treatment options for the radi-
cal cure of Plasmodium vivax malaria are now avail-
able. At the 2019 annual meeting of the Vivax
Working Group of the Asia Pacific Malaria Elimina-
tion Network, participants took part in a roundtable
discussion to identify further evidence required to
introduce these new tools into policy and practice.
Key gaps identified were accuracy and reliability of
glucose-6-phosphate-dehydrogenase deficiency tests,
health system capacity, and feasibility and cost effec-
tiveness of novel treatment strategies in routine clini-
cal practice. As expected, there were differences in
the priorities between country partners and
researcher partners. To achieve the 2030 target for
the regional elimination of malaria, evidence to
address these issues should be generated as a matter
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of priority. Review of global guidelines alongside
locally generated data will help to ensure the timely
revision and optimisation of national treatment
guidelines that will be vital to meet regional elimina-
tion goals.
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1 | INTRODUCTION
Plasmodium vivax malaria continues to exert huge public health burden in the Asia-Pacific
region, South America and the Horn of Africa with more than 14.3 million clinical cases in 2017
(Battle et al., 2019). Major gains have been made in reducing this burden that reflects, in part,
sustained global attention to malaria and renewed attention to the United Nations' Sustainable
Development Goals (SDG). However, these successes in disease control are often focal in nature,
vulnerable to reversal and consequently threaten national, regional and international health
security. In 2014, governments in the Asia-Pacific region committed to eliminating malaria by
2030 (Department of Foreign Affairs and Trade, 2014). Until recently, efforts to
control and eliminate P. vivax malaria were limited by the availability of effective radical
cure options.
Currently, the treatment for P. vivax malaria recommended in most countries in the
Asia-Pacific and the Horn of Africa is a combination of a blood schizonticide such as
chloroquine (CQ) or an artemisinin combination therapy (ACT) plus a 14-day course of
primaquine (PQ) to kill the dormant liver stages called hypnozoites (World Health
Organization [WHO], 2015b). In these regions, a supervised course of PQ14 (at a dose of
3.5 mg/kg total dose) has variable efficacy—achieving greater than 70% at 6 months in some,
but not all locations (John et al., 2012; Llanos-Cuentas et al., 2019). However, in reality, there
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are several challenges including the lack of implementation of radical cure policies (Recht
et al., 2018) resulting in low prescription rates often due to concerns about haemolysis in
patients with glucose-phosphate-dehydrogenase deficiency (G6PD) (Ley et al., 2017). But even
if policies are implemented, the low adherence to a prolonged course of treatment results in
lower effectiveness (Abreha et al., 2017; Douglas et al., 2017; Ley et al., 2017).
While the burden of malaria continues to fall across the Asia-Pacific, the proportionate
burden of P. vivax malaria cases has increased, highlighting the importance of improving the
radical cure of malaria to achieve the 2030 target for regional elimination (APMEN, 2019).
The recently published Lancet Commission highlights the need and feasibility of malaria elim-
ination but also emphasises the importance of accelerating the introduction of novel strategies
(Feachem et al., 2019). In the last 12 months, there have been three major advances in the
tools available to tackle P. vivax relapses: (i) a short course high daily dose PQ regimen
(Taylor et al., 2019); (ii) a novel quantitative point-of-care G6DP test (Alam et al., 2018; Pal
et al., 2019); and (iii) single dose Tafenoquine (TQ) (Lacerda et al., 2019; Llanos-Cuentas
et al., 2019). While broad global policy recommendations addressing the use of those tools are
expected from the World Health Organization's (WHO) Global Malaria Programme (GMP)
within the next 1 or 2 years, the adoption of new tools will need to be tailored to individual
country needs and capacities. After 60 years of limited biotechnical innovation for the control
of P. vivax malaria, National Malaria Control Programs (NMCPs) are now faced with the
challenge of deciding between several new strategies. Options include, but are not limited to,
improving adherence to current guidelines, introducing quantitative or qualitative G6PD
testing with current treatment, shorter high dose PQ regimens and TQ with quantitative
G6PD testing. Introduced strategies may include a mix of these options at different levels of
the health system to be rolled out simultaneously or as phased implementation depending on
the country context and capacity.
Considering that globally the estimated time between the availability of scientific
evidence and its introduction into clinical practice is approximately 17 years (Balas &
Boren, 2000; Green et al., 2009; Morris et al., 2011; Trochim, 2010; Westfall et al., 2007),
we aimed to bring policymakers together to bridge this gap at the same time that NMCPs
are preparing revisions of their National Strategic Plans (NSP) and Global Fund
(GF) concept notes. Previous experience with policy changes and their implementation for
the treatment of falciparum malaria further highlights the need to institutionalise national
malaria policy review and improve communication regarding treatment policy at all levels
(Amin et al., 2007; Kamya et al., 2002; Mulligan et al., 2006; Shretta et al., 2000; Williams
et al., 2004). Key recommendations suggested are to improve communications from
government to health worker level to support implementation, inclusion of pharmaceutical
companies in the process to ensure timely registration of novel drugs, active lobbying by
the international community to ensure funding for novel tools at country level and to
ensure that countries address national level questions in a timely manner
(Kshirsagar, 2006; Williams et al., 2004).
NMCPs and national policymakers must consider several factors when revising treatment
policies including the available scientific evidence, WHO recommendations, country-specific
considerations regarding malaria epidemiology and G6PD deficiency (including in-country
heterogeneity), local socio-ecological variations, cost-effectiveness, logistics and health system
capacity. Countries' national planning cycles include National Strategic Plans (NSP), Mid
Term Reviews (MTR) and Malaria Programme Reviews (MPRs) which again affect the timely
approval of new policy. In addition, many NMCPs rely on external funding from
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organisations such as the GF that influence decision-making and timelines at country level.
The GF, in turn, relies on WHO prequalification and policy guidance for new tools at the
global level. Factors influencing the uptake of these tools include NMCP or Ministry of
Health perceptions of ownership of research (countrywide and on a larger scale), the timeli-
ness at which evidence becomes available, the reliability of research data, available funding
and cost-effectiveness (Nutley et al., 2007; Peters, 2018; Smith, 2013). Finally, the incentive to
implement the process of policy change can be driven by national goals such as the target
for malaria elimination.
In 2019, the Asia Pacific Malaria Elimination Network's (APMEN) Vivax Working Group
(VxWG) convened its annual meeting in Kathmandu, Nepal, and was attended by over 140
participants. Roundtable discussions and a workshop were held to identify evidence gaps and
potential research questions pertinent to NMCPs' policy change processes in a timely manner.
The aim was to identify these questions as NMCPs are preparing revisions of their NSPs and GF
concept notes. While countries await the revisedWHO global recommendations, which are antic-
ipated by mid-2021, NMCPs and regional policymakers need to consider the additional informa-
tion required to initiate country-level changes once these recommendations are in place.
This article explores the additional evidence required by NMCPs that aim to initiate policy
change to implement safe and more effective radical cure for P. vivax malaria. It highlights the
common issues faced, as well as country-specific questions that need to be addressed. The aim
of this work was to facilitate an NMCP-guided translational research agenda for the short to
medium term to assist the decision-making processes for the potential introduction of novel
radical cure strategies.
2 | METHODS
2.1 | The Vivax Working Group of the Asia Pacific Malaria
Elimination Network (APMEN)
The VxWG of the APMEN was formed in 2009 at the network's inaugural meeting. P. vivax was
identified as a critical challenge for regional malaria elimination. The group now
comprises representatives from 21 NMCPs, research partners, the WHO, as well as key funding,
global health and industry stakeholders. Together with the Asia Pacific Leaders Malaria Alliance
(APLMA), APMEN forms a collaborative network working to overcome the challenges to elimi-
nating malaria in the Asia-Pacific region (Thriemer et al., 2017, 2018; Vivax Working
Group, 2015). Over the last 9 years, the VxWG has fostered dynamic interactions between stake-
holders to guide the development and optimisation of tools and products for the diagnosis and
treatment of P. vivax. With the availability of novel tools (Alam et al., 2018; Lacerda et al., 2019;
Llanos-Cuentas et al., 2019; Pal et al., 2019; Taylor et al., 2019), the time has now come to shift the
focus from product development to the implementation of these tools into policy and practice.
2.2 | Participant characteristics
All participants taking part in the main annual meeting were included in the
roundtable discussion and were categorised into two groups: country partners (CPs) comprising
delegates from NMCPs, and research partners (RPs). RPs included researchers from endemic
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countries and non-endemic countries, Civil Society Organisations (CSOs), Product Develop-
ment Partnerships (PDPs), manufacturers, donors, WHO, APMEN and APLMA. During the
consequent workshop, only CPs participated. Three post-meeting interview CP participants
were selected based on their availability in the weeks after the meeting and all three inter-
viewees were present during both the main meeting and the workshop.
2.3 | Data collection
Data was collected in roundtable discussions at the annual meeting, in a consequent CP work-
shop and in follow-up interviews with select CPs who attended the annual meeting.
2.3.1 | Roundtable discussions
During the main meeting, a roundtable discussion was held, focusing on defining the
evidence gaps relevant for policy change. The aim of these discussions was to initiate dia-
logue around what evidence was required to implement national level policy change for
adopting novel radical cure options. Conference attendees were allocated to separate tables
for CPs and RPs to ensure opinions were captured differentially. CP table allocation was
done across subregions to encourage diversity of opinions on each table. In the case of the
CPs, there were three tables with 12–14 participants each. RPs were represented in six tables
with 10–11 participants each. Each table had a facilitator and a note taker to ensure that
table discussions were focused, and discussion outcomes were recorded accurately
(Appendix A). Prior to the meeting, facilitators and note takers were briefed on the key
objectives of the discussions. At the end of the discussions, the CP tables presented their
discussion outcomes to the plenary. Outcomes from the RP discussion were collated
separately. Notes and outcome summaries were used for data analysis.
2.3.2 | Workshop
Following the initial two-day meeting, a workshop restricted to CPs was held to explore the
additional evidence required by each country to develop a road map for policy change and
implementation. CPs were divided into nine discussion tables (with 2–3 countries per table)
and each table was allocated a facilitator and note taker. Workshop discussions were based on
the assumption that a WHO recommendation was available for high dose short course PQ and
TQ. Directly after the end of the roundtable discussions of the main meeting and in a
consultative process with the facilitators, the authors distilled nine research questions relevant
for policy change. The questions were written on flipcharts and participants were asked to rank
them by priority.
2.3.3 | Follow-up interviews
Follow-up Skype or email semi-structured interviews were held with three CPs—Ethiopia, Indo-
nesia and Cambodia—in November and December 2019. The objectives of these additional
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interviews were to verify the priority research questions ranked during the workshop, investigate
if any further evidence gaps had been identified after the workshop and understand if further dis-
cussion with other NMCPmembers may have altered priority questions.
2.4 | Data analysis
Our approach to analysis was qualitative and semi-quantitative, as follows:
2.4.1 | Group discussion analysis
Notes from discussions of both CPs and RPs were analysed to identify research topics that both
groups perceived as important for policy change. To further understand the relative importance
of each research topic to the two groups, all notes were combined, and a count made of the
frequency with which each of the emergent research topics were discussed—we refer to these
as research topic frequency scores.
In addition, all notes for CPs and RPs were combined and a word cloud generated to con-
ceptualise emerging major themes—this consisted of a visual representation of text data with
words weighted by their frequency of use in a document. The word cloud was created using the
online software tool http://www.wordclouds.com by merging all group work notes, removing
country names, correcting spelling, and checking frequently used words for variances in how
they were expressed (for instance PQ-14 and 14-day PQ were both expressed as PQ14). Once the
word cloud was generated, the frequent word list was double-checked for duplicated words with
incorrect spelling or similar meanings.
2.4.2 | Prioritisation of research topics
During the workshop, facilitators developed a list of research topics that emerged from the
roundtable discussions of both CPs and RPs. A total of nine topics areas were developed. During
the workshop, CPs were asked to prioritise research questions they perceived as important for
policy change by ranking them from a score of 1 (the highest priority) to 5 (the lowest).
Questions which were not ranked by participants were given a score of six. The average country
priority ranking for each research question was then calculated to identify the most important
research questions.
2.4.3 | Semi-structured interviews
One interview was conducted via Skype and notes were taken, and the two other interviews
were done via email. All transcripts were manually coded for confirmed priority areas, novel
priority areas, potential other opinions and future actions. Passages of text were read, and codes
assigned based on themes, and examined for frequency, trends, similarities, and differences.
When necessary, direct speech in the results section was corrected for grammatical errors to
improve readability; words added by investigators to improve clarity were marked by
square brackets.
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2.4.4 | Comparison of country partner and research partner priorities
We compared RP and CP priority topics by assessing research priority frequency scores from
group discussions. As there were twice the number of RPs than CPs during discussion groups,
we incorporated CP ranking of research topics into the CP frequency scores by multiplying the
original frequency score by average rank scored. We adapted lessons learned expressed in
Williams et al. (2004) to develop a continuum of policy change along which we plotted research
topic frequency scores. Four key phases were identified up to policy change: (i) current imple-
mentation; (ii) clinical studies to guide global policy; (iii) national adaptation of new tools; and
(iv) national policy change to new tools. Research topics related to current practice were
included under ‘current implementation’. Efficacy trials were included under ‘clinical studies’
and ‘national adaptation of new tools’ included feasibility and effectiveness studies—or any
studies that would allow CPs to assess the use of new tools within their respective health sys-
tems. ‘National policy change’ included elements such as translation of evidence and coordina-
tion between RPs and CPs. The placement of circles for research topics along the continuum of
change was done by two authors and agreed through follow-up discussions. Topics were repre-




A total of 43 CPs and 97 RPs attended the meeting (Appendix B and Appendix C). CP represen-
tation within the Asia-Pacific region included participants from Afghanistan (n = 2), Bangla-
desh (n = 1), Bhutan (n = 3), Cambodia (n = 2), China (n = 1), India (n = 2), Indonesia
(n = 2), Lao (n = 3), Malaysia (n = 2), Nepal (n = 10), Pakistan (n = 1), the Philippines (n = 1),
Papua New Guinea (PNG) (n = 1), Republic of Korea (n = 2), Solomon Islands (n = 2), Sri
Lanka (n = 2), Thailand (n = 2), Vanuatu (n = 1) and Vietnam (n = 2). An additional observer
from Ethiopia (n = 1) also attended. Among the 97 RPs there were 39 (39.8%) researchers from
endemic countries, 24 (24.7%) researchers from non-endemic countries, 7 (7.2%) representatives
from CSOs, 10 (10.3%) delegates from PDPs, 3 (3.1%) manufacturers, 1 (1.0%) international
WHO representative and 2 (2.1%) officials from the WHO office in Nepal, 3 (3.1%) APMEN rep-
resentatives, 3 (3.1%) APLMA officials and 3 (3.1%) donor representatives. Most researchers
from both endemic and non-endemic countries had a biomedical research focus including clini-
cal and lab science or modelling and statistics skills (92.1%; 58/63) and 5 (7.9%) participants
worked in the field of social science or had a health economics focus.
3.2 | Key research questions identified by country partners during
main meeting
The most frequent topics identified as being key to inform policy change and implementation
were cost-effectiveness and cost–benefit, understanding policy change processes, operational
feasibility and health system capacity, G6PD test accuracy and reliability, treatment efficacy
and G6PD prevalence. In addition, safety, drug acceptability, treatment effectiveness and adher-
ence and P. vivax prevalence were also ranked as important (Appendix D and Appendix E).
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3.3 | Key research questions identified by research partners during
main meeting
Research areas, questions and topics identified by the six RP tables during the meeting
encompassed a wide variety of issues. Overarching topics included the safety and
appropriate testing for G6PD, effectiveness and adherence of radical cure options,
operational feasibility and health care system capacity (Table 1 and Figure 1). RPs also
highlighted other challenges, beyond research, that require better understanding or strengthen-
ing such as variations in government regulation of the public and private health sector in differ-
ent APMEN countries that affects policy regulation, revision and implementation.
Understanding P. vivax epidemiology and associated mortality to facilitate advocacy as well as
the need to improve communication with patients to highlight the benefits of radical cure were
also mentioned.
3.4 | Prioritisation of questions by country partners during the
workshop
To clarify which of these topics had the highest priority for CPs, nine key questions were dis-
tilled after the initial discussions at the main meeting. These included: (i) What is the effective-
ness of different treatment options (14 day low dose PQ (PQ14), 7 day high dose PQ (PQ7), TQ)
TABLE 1 Evidence gaps and research questions identified by research partners
Overarching topics Identified evidence gaps and research questions
Safety and appropriate testing
for G6PD
• How good is the reliability and field applicability of G6PD tests?
• Is a single time point to test for G6PD activity sufficient (i.e., one life-
long diagnosis)?
• How to conduct effective training G6PD testing including QC?
• What is the more comprehensive picture on G6PD deficiency levels
across different populations?
• Country-specific data on the adverse effects of PQ and TQ is required
as well as better definitions to describe, predict and manage
haemolytic events
Effectiveness and adherence of
radical cure options
• Lack of comparative effectiveness data between PQ7 and PQ14 and TQ
• Limited evidence to support country claims that PQ14 is working
• In which areas is low dose PQ with increased adherence (supervision)
sufficient?
• Pragmatic qualitative studies on adherence
Feasibility and health care
system capacity
• Need for large-scale implementation and feasibility studies particularly
in large countries such as Indonesia and India with many ethnic
groups
• Cost-effectiveness on subnational level
• Pharmacovigilance strengthening
• Feasibility of implementation of different radical cure options on
primary, secondary, and tertiary health care levels
• Operational challenges for roll out of easy-to-use, safe and reliable
G6PD testing
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FIGURE 1 Word cloud identifying key topics from research partner discussions
TABLE 2 Average ranking of country research priorities, with 1 being highest priority and 5 lowest (no




What is the effectiveness of different treatment options (PQ14, PQ7, TQ) and adherence
between different regimens?
2.6
How well do new diagnostics work in the field (usability, robustness, etc.)? 3.9
What is the best way to improve patients' adherence? 4.1
What is the cost effectiveness of different regimen options? 4.4
Feasibility of new interventions at different levels of health system
(including supply chain capacity and quality assurance)?
4.4
What is the prevalence of G6PD deficiency in my country? 4.4
How can we ensure safe delivery of the different options? 4.9
How effective is the current practice? 5.3
What are the overall vivax dynamics in my country? 5.6
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and adherence between different regimens? (ii) What are the overall vivax dynamics in my
country? (iii) How effective is current practice? (iv) What is the prevalence of G6PD deficiency
in my country? (v) How well do new diagnostics work in the field (usability, robustness, etc.)?
(vi) How can we ensure safe delivery of the different options? (vii) What is the cost effectiveness
of the different regimens? (viii) Feasibility of new interventions at different levels of health
system (including supply chain capacity and quality assurance)? (ix) What is the best way to
improve patients' adherence?
Of these nine research questions, CPs ranked effectiveness of different radical cure options
as the highest priority followed by questions around how well G6PD diagnostics work in the
field. Evaluating methods to improve adherence was ranked as the third priority. Cost-effective-
ness of different options and feasibility as well as more data on G6PD prevalence within coun-
tries were ranked equally following the initial three priorities (Table 2). There were significant
differences in rankings by country (Appendix F).
3.5 | Validation of country partner priority research topics
3.5.1 | Confirmation of priority ranking
All three CP participants interviewed confirmed that the priorities developed during the
APMEN VxWG workshop remain priorities even after discussion with other NMCP
members.
The efficacy and effectiveness of PQ7 remained the top-ranking question for Cambodia:
We don't know about the efficacy of PQ treatment plans, but we think that 7-day
dose might be appropriate, and an increased dose might be effective, based on what
other APMEN countries are doing also. (Cambodian NMCP representative)
The Indonesian NMCP representative confirmed that feasibility studies are their priority
whereas the Ethiopian representative highlighted that operational feasibility of novel tools and
cost effectiveness of G6PD testing at community level were the most pressing questions to
address for their country as well as assessing gaps in current practice.
We need to assess whether new policy related to vivax radical cure could be
implemented in a routine situation. (Indonesian NMCP representative)
It is good first to have conclusive evidence that shows the current practice has
adherence issues. If not, the decision might be to continue with PQ14 to be on the
safe side. (Ethiopian NMCP representative)
3.5.2 | Other opinions within the NMCPs
The Cambodian and Indonesian respondents reported that other NMCP colleagues and their
respective Ministries of Health are also in agreement that these are each of their countries' key
priorities. The Indonesian NMCP discussed these priorities with their national expert commit-
tee on October 24, 2019 after the 2019 APMEN meeting and before the interview, suggesting
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that there is a reasonable consensus within this expert community. However, the Indonesian
respondent mentioned that there might be other opinions with diverging priorities at a higher
Ministerial level. The Ethiopian respondent highlighted the need to reach full consensus among
decision-makers and that more discussions were needed within the country.
3.5.3 | Future action
In line with the identified priorities, Cambodia planned pilot studies to inform potential policy
change.
Cambodia will only implement evidence-based policy. We plan to investigate PQ7
and we would also like to explore how to implement TQ starting in the military.
(Cambodian NMCP representative)
Similarly, feasibility studies were planned in Indonesia and in Ethiopia to generate data to
support decision-making.
TQ is not a priority at this point, we have huge amount of P. vivax. So, to minimise
any unintended consequence as a result of this drug, we have to wait for some time
[and gather more evidence]. (Ethiopian NMCP representative)
For Indonesia and Ethiopia, respondents mentioned that this did not yet influence national
planning whereas in Cambodia these plans were closely linked to the currently developed NSP
and these activities will be included in an upcoming application to the GF.
3.6 | Research priorities on the continuum of change
By combining CP topics and ranking into frequency scores, the highest priority topics raised by
CPs became the use and reliability of point-of-care (PoC) G6PD tests on a par with cost-effec-
tiveness of new tools, G6PD prevalence, and feasibility and health system capacity, closely
followed by patient adherence and effectiveness of novel treatment options (Figure 2). CPs
emphasised costing, budget impact and cost–benefit analysis as well as cost-effectiveness. Lower
ranked priorities were P. vivax prevalence, current treatment effectiveness, understanding
change processes, drug acceptability and safety. RPs prioritised patient adherence and effective-
ness, safety, and feasibility and health system capacity. Additional priorities that were ranked
lower were drug acceptability and cost-effectiveness. The lowest ranked topic by RPs was
P. vivax prevalence.
The greatest overlap between CPs and RPs was the need to understand the operational feasi-
bility of implementing new tools in country health systems which was similarly ranked between
CPs and RPs. Treatment effectiveness and patient adherence was the next greatest overlap
followed by cost effectiveness and cost–benefit of different treatments. The greatest divergence
between partners was regarding G6PD PoC accuracy and reliability, safety, and cost-effective-
ness. CPs highlighted the need to understand policy processes including how to better increase
uptake of evidence into policy. RPs tended to highlight the need to map P. vivax prevalence or
mortality to highlight to policymakers the need for vivax to be prioritised. Finally, research
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topics of interest to both CPs and RPs clustered around the national adaptation or con-
textualisation of new tools with CPs highlighting the need to understand policy processes or
how to translate results from studies into guidance (Figure 2).
4 | DISCUSSION
P. vivax malaria continues to be a major global public health threat. In the Asia-Pacific region
and the Horn of Africa, the highest caseloads are often in remote communities where access to
healthcare is poor. With the recent approval of and evidence for the efficacy of new tools for
better radical cure (Lacerda et al., 2019; Llanos-Cuentas et al., 2019; Taylor et al., 2019;
White, 2019), discussions were facilitated to identify key research questions faced by CPs seek-
ing to adapt new tools into their respective settings. The overall results of our analysis highlight
a call by CPs for additional national-level evidence around PoC G6PD accuracy and reliability,
operational feasibility of radical cure options within health systems and cost-effectiveness anal-
ysis of new tools. This work highlights key questions CPs will face when aiming to change
national policy and proposes areas which researchers and donors can focus their work and
resources on. It indicates the need for an increased understanding of treatment effectiveness
under real-life conditions as compared to efficacy which is measured in carefully controlled set-
tings (Thriemer et al., 2017). This is in line with questions faced by CPs around a national level
understanding of how to incorporate these new tools into clinical practice. Previous work on
malaria treatment policy change highlights the importance of undertaking effectiveness studies
as well as efficacy studies to drive policy change (Durrheim & William, 2005). Countries need
to contextualise research findings and global policy recommendations to suit their countries'
socio-economic needs and specific epidemiological contexts (Davis & Walker, 2019). Those
studies are crucial to support policy change and ‘bridge the "know–do" gap’ as highlighted
FIGURE 2 Research areas/topic priorities for country and research partners plotted along the continuum of
change. Notes: Topics identified in the main meeting and the workshop are represented by circles. Circle sizes
represent the frequency of topic discussed, with larger circles representing higher frequency
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previously (WHO, 2005). Health policy change is complex requiring different types of evidence
along the continuum of change (Lewin et al., 2012; Peters & Bennett, 2012). Malaria programs
have the benefit of receiving global guidance from the WHO that collates and assesses global
clinical trial and safety data for new treatments. However, WHO guidance is global by necessity
thus early country adopters of new tools often need to determine whether and how these tools
will work in their local contexts.
The need for greater understanding of PoC G6PD accuracy and reliability prior to policy
change was prioritised by CPs and RPs indicating the need to pilot new G6PD diagnostic tools
especially before implementing TQ or high dose PQ regimens. Both CPs and RPs expressed con-
cerns regarding drug tolerability and safety. However, in this context, CPs seem to express this
as ‘wanting to better understand the reliability of G6PD tests’ to ensure that these tools will cor-
rectly identify G6PD deficient (or intermediate) patients when used in tandem with higher dose
regimens. Historically, the availability of G6PD PoC tests has been very limited. NMCPs' expo-
sure to quantitative tests, which are now in the process of more widespread commercialisation
and availability, has been limited but concerted efforts have been undertaken by partners to
raise awareness of these products and how they can be used to support malaria control and
elimination goals (Ley et al., 2015). The difference in the level of priority given to PoC G6PD by
RPs and CPs likely reflects an asymmetry in information between the two groups possibly indi-
cating the need for better knowledge transfer through synthesis and accessible presentation of
G6PD literature as well as further studies to answer CPs' questions. Discussions also highlighted
the need to have a broader understanding about safety of radical cure away from a focus on
adequate testing only to a more holistic approach, including adequate detection of early signs of
haemolysis and risk mitigation strategies.
While both CPs and RPs expressed the need for feasibility studies, there was little discussion
as to what exactly should be included in these studies. RPs highlighted the need to understand
how pharmacovigilance systems could be strengthened down to the lowest levels where new
tools could be used. This could indicate that feasibility for CPs and RPs means understanding
how new tools will be deployed within the health system. Previous qualitative research to
understand the processes and timelines for the introduction of ACTs and mandatory confirma-
tion of malaria prior to treatment (Ajayi et al., 2008; Swana et al., 2016) indicates that explor-
atory studies provide useful and effective pre-implementation data. Other health system
elements highlighted from previous research on malaria treatment policy change pathways
include increasing the uptake of integrated community case management (iCCM) (WHO, 2018)
and strengthening the health workforce (WHO, 2015a) to manage the use of novel tools. This
begs the question as to how and at what cost can countries provide adequate supportive super-
vision to their health workforce to ensure effective and safe radical cure, particularly when
scaled up.
Cost-effectiveness studies on new tools and treatment regimens were also raised by CPs
and RPs. Some countries require Cost-Effectiveness Analyses (CEA) to allow the incorpora-
tion of new tools into insurance schemes (Escribano Ferrer et al., 2017; Hansen et al., 2017).
In the APMEN region, China, Malaysia, Philippines and Thailand have a requirement for
Health Technology Assessments (HTA) of new tools (Sivalal, 2009) akin to the NICE process
in the United Kingdom (NICE, 2019), but this is not a requirement in most regional coun-
tries. The HTA requirement is likely correlated to the proportion of the malaria programs
supported by domestic versus external funding. Some countries are more reliant on GF for
procurement of tools which need to be WHO approved or prequalified prior to GF procure-
ment (Pigott et al., 2012). Others have substantial domestic budgets that may require
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different sets of evidence or information for policy change (Pigott et al., 2012). While lim-
ited, some CPs discussed the need for cost–benefit analysis and budget impact studies in
addition to cost-effectiveness. This likely reflects their cognizance of having to advocate for
additional resources within their respective ministries of health, providing cost data in differ-
ent ways to do so.
Understanding policy change processes and uptake of evidence was also raised. CPs
requested more and better translation of evidence into policy especially by neutral or non-
technical parties who could translate evidence into simple language. In addition, they specified
the need for stronger coordination with researchers and better understanding of regulatory and
policy change pathways (see Figure 2). The gap between scientific recommendations based on
research findings and countries' motivations to change policy is often difficult to bridge
(Smith, 2013). CPs' requests align with findings from Smith's review of knowledge transfer in
which an increase in the use of research into policy and practice explored the following strate-
gies: ‘ensuring research is accessible’, ‘developing ongoing, collaborative relationships’,
‘improving structural communication channels’ and ensuring that there are sufficiently high
incentives among researchers and research users to engage in knowledge exchange
(Smith, 2013, p. 21).
CPs were also keenly aware of their implementation needs and unsurprisingly were con-
cerned about the success of current treatment practice which will need to continue beyond
feasibility studies while countries await global WHO guidance. In addition, G6PD deficient
patients will continue to receive either the current standard treatment or 8-week
PQ. Understanding current adherence rates and reasons for non-adherence will be essential
for designing more effective behaviour-centred strategies to improve the effectiveness of cur-
rent regimens (Aunger & Curtis, 2016). RPs agreed with CPs regarding the need to assess
current treatment guidelines but more from the perspective of proving that those treatments
have low effectiveness (Abreha et al., 2017; Douglas et al., 2017; Maneeboonyang
et al., 2011; Takeuchi et al., 2010) and thus strengthen the advocacy and business case for a
policy change.
There are several limitations to this work. First, although APMEN serves as a unique forum
for exchange between the research community and NMCPs, inevitable time restrictions prevent
in-depth discussions and more detailed analysis. CPs often have greater experience and capacity
in policy implementation than in identifying and commissioning research to suit country needs.
Second, topics raised by RPs are shaped by their expertise and knowledge background, which
is biased towards clinical and basic science with a lack of expertise in the fields of policy and
health system research as well as limited participation by scientists with behavioural and social
science backgrounds. This might also explain why participants did not raise topics around partic-
ular strategies to provide treatment to mobile populations and other hard-to-reach populations.
Third, the selection of research questions used for the ranking was done ad hoc at the end
of the main meeting without considering the more detailed notes from each of the tables due to
time limitations.
Fourth, there is a risk of potential power imbalance between RPs and CPs as RPs tended to
be either native English speakers or have a very good working knowledge of English and were
more confident in expressing their views. Whereas CPs may be less confident in expressing their
views in English despite being highly knowledgeable in their country context. This results
in CP voices often being heard less. To address this issue, roundtable discussions during the
main meeting were separated for CPs and RPs and a follow-up workshop was held exclusively
for CPs.
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Fifth, follow-up interviews to verify some of the discussion outcomes were only held with
three NMCPs. Interview participants were selected based on their availability within the time-
frame of writing this article. Further in-depth investigation is warranted to fully understand the
evidence gaps.
Sixth, average priority scores across the region only have limited significance and given the
heterogeneity between countries, localised research agendas need to be developed. In addition,
individual CPs might not accurately represent country program priorities, but might be biased
based on the specific area of work within the respective programs.
Seventh, the methods used to obtain frequency scores combined the average ranking of
countries with roundtable scores to consider fewer CP than RP participants which could have
skewed priorities towards those that were ranked.
Finally, we attempted to position research questions along a continuum of policy change
while acknowledging that change is an iterative, non-linear process that is influenced by many
factors beyond evidence that require better understanding. As well as defining these evidence
gaps, there is a need to understand the political economy of policy change processes. Providing
data on ongoing research for CPs to draw from for timely decision-making, packaging evidence
in a manner that it translates clearly from RPs to CPs and continuing to strengthen the commu-
nication interface between RPs and CPs is also ideal. Work addressing these needs has already
started and will inform policy change in the short and long term.
5 | CONCLUSION
The safe and effective roll out of radical cure has repeatedly been identified by CPs as one of
the major challenges of moving towards malaria elimination in vivax endemic countries
(Thriemer et al., 2017). With the availability of novel tools and treatment strategies, the Asia-
Pacific target of elimination within the next 10 years appears more feasible. However, given the
relatively short timeframe to achieve this 2030 target, the evidence gaps identified in our meet-
ings need to be addressed urgently so that results become available at the same time as WHO
provides a policy recommendation and revised global guidance on P. vivax treatment—
anticipated in mid-2021. This would enable NMCPs to examine global recommendations along-
side nationally generated data relevant to their respective contexts.
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Eijkman-Oxford Clinical Research Unit, Indonesia Kevin Baird
Ethiopian Public Health Institute, Ethiopia Adugna Woyessa
Ethiopian Public Health Institute, Ethiopia Ashenafi Assefa
FIND, Switzerland Christian Ghergu
FIND, Switzerland Rosalind Howes
GSK, UK Andy Walker
icddr,b, Bangladesh Wasif Khan
Institute of Cholera and Enteric Diseases, India Arunansu Talukdar
Institute of Cholera and Enteric Diseases, India Santasabuj Das
Institute of Tropical Medicine, Belgium Charlotte Gryseels
Kasturba Medical College, India Kavitha Saravu
London School of Hygiene & Tropical Medicine, UK Henry Suhendra
Mahidol Vivax Research Center, Thailand Wang Nguitragool
Mahidol Vivax Research Center, Thailand Wanlapa Roobsoong
Malaria Atlas Project (MAP), UK Katherine Battle
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Malaria Medicines Venture (MMV), Switzerland Melanie Larson
Malaria Medicines Venture (MMV), Switzerland Caroline Lynch
Malaria Medicines Venture (MMV), Switzerland Eric-Marie Dupuy
Malaria Medicines Venture (MMV), Switzerland George Jagoe
Menzies School of Health Research, Australia Angela Devine
Menzies School of Health Research, Australia Daniel Pfeffer
Menzies School of Health Research, Australia Jutta Marfurt
Menzies School of Health Research, Australia Kamala Thriemer
Menzies School of Health Research, Australia Matthew Grigg
Menzies School of Health Research, Australia Ric Price
Menzies School of Health Research, Australia Robert Commons
Menzies School of Health Research, Australia Sophie Weston
Menzies School of Health Research, Australia Varunika Ruwanpura
Mahidol-Oxford Research unit (MORU), Thailand Cindy Chu
Nangarhar University, Afghanistan Awab Ghulam Rahim
National Institute of Malariology, Parasitology and Entomology (NIMPE),
Vietnam
Bui Quang Phuc
Oxford University Clinical Research Unit (OUCRU), Vietnam Nguyen Chau
Oxford University, UK Bipin Adhikari
Papua New Guinea Institute of Medical Research, PNG Livingstone Tavul
Pasteur Institute, France Narimane Nekkab
PATH, US Nick Luter
PATH, US Sampa Pal
PATH, US Spike Nowak
PATH, US Vajra Allan
Population Services International (PSI), Lao Kemi Tesfazghi
Population Services International (PSI), Myanmar Phone Si Hein
Research Institute for Tropical Medicine, Philippines Effie Espino
Research Institute for Tropical Medicine, Philippines Veronica L. Tallo
Retired Malaria Specialist, Nepal Garib Das Thakur
Retired Malaria Specialist, Nepal Padam B Chand
Save the Children, Nepal Suman Thapa
SD Biosensor, Korea Eun Kang Ye
Sukra Raj Tropical & Infectious Disease Hospital, Nepal Basudev Pandey
Swedish Committee for Afghanistan, Afghanistan Mohammad Anwar
Tribhuvan University, Nepal Binad Dhungal
Tribhuvan University, Nepal Jeevan B Sherchand
(Continues)
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ACCESSBIO Young S Hong
Tribhuvan University, Nepal Keshab Parajuli
Tribhuvan University, Nepal Komal Raj Rijal
Tribhuvan University, Nepal Megha Raj Banjara
Tribhuvan University, Nepal Naba Raj Adhikari
Tribhuvan University, Nepal Prakash Ghimire
Tribhuvan University, Nepal Upendra Thapa Shrestha
US President's Malaria Initiative/USAID, Myanmar Nu Nu Khin
UCSF Global Health Group, US Adam Bennett
Unitaid, Switzerland Katerina Gallizzo
University of Gadjah Mada, Indonesia Supargiyono Supargiyono
University of Indonesia, Indonesia Erni Nelwan
University of Indonesia, Indonesia Inge Sutanto
University of Melbourne, Australia Julie Simpson
University of Sumatera Utara, Indonesia Ayodhia Pitaloka
University of Sumatera Utara, Indonesia Inke Nadia Diniyanti
Lubis
University of Western Australia, Australia Brioni Moore
University of Western Australia, Australia Laurens Manning
Vector Borne Disease Research and Training Centre, Nepal Yadu Chandra Ghimire
Walter and Eliza Hall Institute (WEHI), Australia Robert James
Walter and Eliza Hall Institute (WEHI), Australia Harin Karunajeewa
WHO, Nepal Lungten Wangchuk
WHO, Nepal Jos Vandealor
WHO, Switzerland Jane Cunningham
WorldWide Antimalarial Resistance Network, UK Philippe Guerin
YPKMP Timika, Indonesia Annisa Rahmalia
YPKMP Timika, Indonesia Rini Poespoprodjo
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APPENDIX D: INITIAL EVIDENCE GAPS IDENTIFIED BY COUNTRY PARTNERS
DURING THE MEETING'S ROUNDTABLE DISCUSSION
Discussion
table
number Country partners Identified research areas
1 Afghanistan, Bhutan, Cambodia, India, Lao
(PDR), Malaysia, Pakistan, Papua New
Guinea (PNG), Solomon Islands, Sri
Lanka, Vanuatu, Ethiopia, Democratic
People's Republic of Korea (DPRK),
China
Operational research and policy
implementation research
Better knowledge translation and advocacy
from research organisations for available
evidence
Better understanding of local data and
context including G6PD prevalence in each
country/Countries had different views
regarding whether G6PD data should be
population wide, on specific populations,
or vivax specific.
Further national studies relating to the global
studies for radical cure options
Comparison of efficacy, cost effectiveness,
and safety of PQ7 versus PQ14 versus TQ
2 Afghanistan, Bhutan, China, Indonesia,
Lao (PDR), Nepal, Pakistan, DPRK,
Solomon Islands, Thailand, Vietnam,
Republic of Korea (ROK), Ethiopia, PNG,
Vanuatu
Better coordination between NMCPs and
research institutes in countries
Additional data and research on G6PD
prevalence
Efficacy and accuracy of qualitative and
quantitative G6PD tests
Research on addressing asymptomatic P.
vivax malaria cases
Research on the success of existing malaria
control programmes
3 Bangladesh, Cambodia, India, Indonesia,
Malaysia, Nepal, Philippines, Republic of
Korea (ROK), Sri Lanka, Thailand,
Vietnam, India
Technical evidence on efficacy of new
diagnostic tests
WHO recommendation on new drugs and
the process for drug registration
Operational feasibility based on level of
health system, supply chain factors,
human resource capacity and quality
assurance procedures
Cost benefit analysis for implementing
radical cure and an assessment of the
impact on national health budgets
(Continues)
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Discussion
table
number Country partners Identified research areas
Drug acceptability: for patients and
provider acceptability, this may require
pilot studies.
Development of a regional evidence base to
influence national policy change
APPENDIX E: WORD CLOUD GENERATED FROM INITIAL DISCUSSION AMONG
COUNTRY PARTNERS DURING ROUNDTABLE DISCUSSION
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APPENDIX F: COUNTRY-SPECIFIC RANKINGS OF RESEARCH PRIORITIES
F.1 | Afghanistan
Research question Priority ranking
What is the prevalence of G6PD deficiency in my country? 1
What is the cost effectiveness of different regimen options? 2
What is the effectiveness of different options (PQ14, PQ7, TQ) and
adherence between different regimens?
3
Feasibility of new interventions at different levels of health system
(including supply chain capacity and quality assurance)?
4
What is the best way to improve patients' adherence? 5
F.2 | Bangladesh
Research question Priority ranking
What is the prevalence of G6PD deficiency in my country? 1
How effective is the current practice? 2
What is the effectiveness of different options (PQ14, PQ7, TQ) and
adherence between different regimens?
3
What is the best way to improve patients' adherence? 4
What is the cost effectiveness of different regimen options? 5
F.3 | Bhutan
Research question Priority ranking
What is the prevalence of G6PD deficiency in my country? 1
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
2
What is the cost effectiveness of different regimen options? 3
What are the overall vivax dynamics in my country? 4
How can we ensure safe delivery of the different options? 5
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F.4 | Cambodia
Research question Priority ranking
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
1
What is the cost effectiveness of different regimen options? 2
How can we ensure safe delivery of the different options? 3
How well do new diagnostics work in the field (usability, robustness, etc.)? 4
Feasibility of new interventions at different levels of health
system (including supply chain capacity and quality assurance)?
5
F.5 | Ethiopia
Research question Priority ranking
What is the best way to improve patients' adherence? 1
How can we ensure safe delivery of the different options? 2
What is the prevalence of G6PD deficiency in my country? 3
What is the cost effectiveness of different regimen options? 4
How well do new diagnostics work in the field (usability, robustness, etc.)? 5
F.6 | India
Research question Priority ranking
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
1
How well do new diagnostics work in the field (usability, robustness, etc.)? 2
How can we ensure safe delivery of the different options? 3
What is the best way to improve patients' adherence? 4
What is the cost effectiveness of different regimen options? 5
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F.7 | Indonesia
Research question Priority ranking
Feasibility of new interventions at different levels of health system
(including supply chain capacity and quality assurance)?
1
How well do new diagnostics work in the field (usability, robustness, etc.)? 2
How can we ensure safe delivery of the different options? 3
What is the cost effectiveness of different regimen options? 4
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
5
F.8 | Lao (PDR)
Research question Priority ranking
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
1
How well do new diagnostics work in the field (usability, robustness, etc.)? 2
How can we ensure safe delivery of the different options? 3
What is the best way to improve patients' adherence? 4
Feasibility of new interventions at different levels of health system
(including supply chain capacity and quality assurance)?
5
F.9 | Malaysia
Research question Priority ranking
How effective is the current practice? 1
What is the cost effectiveness of different regimen options? 2
How well do new diagnostics work in the field (usability, robustness, etc.)? 3
Feasibility of new interventions at different levels of health system
(including supply chain capacity and quality assurance)?
4
Not answered 5
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F.10 | Nepal
Research question Priority ranking
What is the best way to improve patients' adherence? 1
How well do new diagnostics work in the field (usability, robustness, etc.)? 2
How effective is the current practice? 3
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
4
Feasibility of new interventions at different levels of health
system (including supply chain capacity and quality assurance)?
5
F.11 | Pakistan
Research question Priority ranking
What are the overall vivax dynamics in my country? 1
What is the prevalence of G6PD deficiency in my country? 2
What is the effectiveness of different options (PQ14, PQ7, TQ) and
adherence between different regimens?
3
How well do new diagnostics work in the field (usability, robustness, etc.)? 4
What is the best way to improve patients' adherence? 5
F.12 | Papua New Guinea (PNG)
Research question Priority ranking
What is the prevalence of G6PD deficiency in my country? 1
What is the best way to improve patients' adherence? 2
Feasibility of new interventions at different levels of health
system (including supply chain capacity and quality assurance)?
3
What is the cost effectiveness of different regimen options? 4
What are the overall vivax dynamics in my country? 5
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F.13 | Solomon Islands
Research question Priority ranking
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
1
Feasibility of new interventions at different levels of health
system (including supply chain capacity and quality assurance)?
2
How well do new diagnostics work in the field (usability, robustness, etc.)? 3
What is the best way to improve patients' adherence? 4
How effective is the current practice? 5
F.14 | Republic of Korea
Research question Priority ranking
What is the effectiveness of different options (PQ14, PQ7, TQ)






F.15 | Sri Lanka
Research question Priority ranking
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
1
Feasibility of new interventions at different levels of health
system (including supply chain capacity and quality assurance)?
2
How well do new diagnostics work in the field (usability, robustness, etc.)? 3
How can we ensure safe delivery of the different options? 4
What is the cost effectiveness of different regimen options? 5
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F.16 | Thailand
Research question Priority ranking
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
1
What is the best way to improve patients' adherence? 2
Feasibility of new interventions at different levels of health
system (including supply chain capacity and quality assurance)?
3
How can we ensure safe delivery of the different options? 4
How well do new diagnostics work in the field (usability, robustness, etc.)? 5
F.17 | Vanuatu
Research question Priority ranking
What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
1
How well do new diagnostics work in the field (usability, robustness, etc.)? 2
What is the best way to improve patients' adherence? 3
How can we ensure safe delivery of the different options? 4





What is the effectiveness of different options (PQ14, PQ7, TQ)
and adherence between different regimens?
1
What is the cost effectiveness of different regimen options? 2
3




Feasibility of new interventions at different levels of health system (including supply
chain capacity and quality assurance)?
How well do new diagnostics work in the field (usability, robustness, etc.)? 4
What is the prevalence of G6PD deficiency in my country? 5
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